In April 2018, Tango Biosciences received a R41 award from NIH. The goals of the grant are to generate two-site capable affinity reagents through MegaSTAR to two sets of targets. One set represents biomarkers of colorectal cancer and myocardial infarction. MegaSTAR reagents will be benchmarked against existing commercial sandwich reagents, and the performance metrics (i.e., intra-assay and inter-assay precision, linearity, sensitivity) will be evaluated and compared through ELISA. The second set of targets is a family of membrane proteins. Successful production of specific affinity reagents to the ectodomains will showcase the potential of MegaSTAR to generate reagents to challenging targets.
NIH STTR award
More News and Events
-
News
Tango Biosciences Appoints Zachary Gurard-Levin, PhD to Board of Directors
Appointment Brings Over Ten Years as a CRO Executive Tango Biosciences, Inc., the premier contract research organization for custom affinity reagents by phage display, announced the appointment of Zachary Gurard-Levin, PhD, to its board of directors effective immediately. Gurard-Levin brings over two decades of experience in assay development and driving successful research programs for biotech […]
-
Event
ACSMEDI-EFMC Medicinal Chemistry Frontiers 2025
Chicago, IL | May 12-15, 2025 Join Tango Biosciences at ACSMEDI-EFMC Medicinal Chemistry Frontiers 2025! Booth CP3 This meeting attracts a highly targeted audience composed of experts and researchers in drug discovery and development. Visit the Tango Biosciences booth to talk to our experts in peptide therapeutics discovery, targeted protein degradation for PROTACs and molecular glues, […]
-
Event
AACR Annual Meeting
Chicago, IL | April 25-30, 2025 Attending the 2025 AACR Annual Meeting? Schedule a meeting with Tango Biosciences experts to talk about your upcoming needs in antibody and affinity reagent discovery! The AACR Annual Meeting is the critical driver of progress against cancer, the place where scientists, clinicians, other health care professionals, survivors, patients, and […]